Skip to content

Insider · CIK 0001744682

Paula Cloghessy

officer

Files at KLRA (Kailera Therapeutics, Inc.). First filing -, latest -.

In brief

Paula Cloghessy files SEC Form 4 as officer at KLRA (Kailera Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.

A track record needs three past buys with six months of prices behind them; Paula Cloghessy has 0, so none is measured yet.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, 2 in all, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Apr 16, 2026KLRA
Kailera Therapeutics, Inc.
AGrant or award
Stock Option (right to buy)derivative
+60,000$0.00$060,000Apr 20, 2026
Apr 16, 2026KLRA
Kailera Therapeutics, Inc.
AGrant or award
Stock Option (right to buy)derivative
+60,000$0.00$060,000Apr 20, 2026

Questions about Paula Cloghessy

Answered from the filings on this page, as of the latest one.

Is Paula Cloghessy buying or selling?

Paula Cloghessy has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.

How did Paula Cloghessy's past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Paula Cloghessy has 0.

Where does Paula Cloghessy file Form 4?

Paula Cloghessy has filed Form 4 at KLRA (Kailera Therapeutics, Inc.) as Chief People Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Paula Cloghessy: insider trades and track record | InsiderTell